AbbVie wins U.S. approval for Parkinson’s treatment
(Reuters) – The U.S. Food and Drug Administration approved AbbVie Inc's treatment for Parkinson's disease, three months ahead of the scheduled review date. The treatment, Duopa — a combination of carbidopa and levodopa — is the first to be effective for 16 hours, compared with existing oral formulations that last for up to four hours following a single dose. Duopa, already available in Canada, is administered using a small portable infusion pump that delivers the drug directly to the small intestine. AbbVie shares were up 1 percent in premarket trading. …
